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PTPN4, a human tyrosine phosphatase, protects
cells against apoptosis. This protection could be
abrogated by targeting the PDZ domain of this phos-
phatase with a peptide mimicking the C-terminal
sequence of the G protein of an attenuated rabies
virus strain. Here, we demonstrate that glioblastoma
death is triggered upon intracellular delivery of pep-
tides, either from viral origin or from known endoge-
nous ligands of PTPN4-PDZ, such as the C terminus
sequence of the glutamate receptor subunit GluN2A.
The killing efficiency of peptides closely reflects their
affinities for the PTPN4-PDZ. The crystal structures
of two PTPN4-PDZ/peptide complexes allow us to
pinpoint the main structural determinants of bind-
ing and to synthesize a peptide of high affinity for
PTPN4-PDZ enhancing markedly its cell death
capacity. These results allow us to propose a poten-
tial mechanism for the efficiency of peptides and pro-
vide a target and a robust framework for the design of
new pro-death compounds.
INTRODUCTION
Tumors develop when, in a healthy organ, cells display uncon-
trolled growth and division beyond the normal limits and escape
cell death mechanisms. Viruses are masters for manipulating the
proliferation or death of the host cell they infect, mainly by inter-
fering with crucial endogenous interactions. The viral sequences
implied in the interference process may lead to the development
of new therapeutic compounds, particularly antitumor reagents
for treating malignant brain tumors, such as glioblastoma, which
are still the cause of high levels of morbidity and mortality.1518 Structure 19, 1518–1524, October 12, 2011 ª2011 Elsevier LtdStudying the molecular basis of rabies virus (RABV) virulence
and attenuation, we showed that one single mutation (Q to E)
at the C terminus of the envelope G protein is sufficient to switch
the fate of the infected cell from survival to apoptosis (Pre´haud
et al., 2010). This residue is located in a PDZ-binding site
(PDZ-BS) and specifies the interaction of the G protein with the
PDZ domains of different cell partners. The Q to E change
increases the number of cellular partners for the PDZ-BS in the
infected cells, the attenuated RABV strain G protein interacting
now with the PDZ domain of the human tyrosine phosphatase
PTPN4 (also known as PTPMEG1, UniProtKB: P29074). PTPN4
is a nonreceptor PTP with functions in TCR cell signaling,
learning, maintaining spatial memory, and cerebellar synaptic
plasticity (Kina et al., 2007). By silencing its encoding gene, we
demonstrated that PTPN4 guards a wild-type cell against
apoptosis. We also showed that cell death can be induced
outside the infectious context by cell-penetrating peptides en-
coding the attenuated strain PDZ-BS (Cyto13-att), but not by
peptides from a virulent strain PDZ-BS (Cyto13-vir) or by
peptides lacking the last four amino acids (Cyto9-D).
PDZ domains play a central role in cell signaling by favoring
spatial contacts between enzymes and their substrates, or
more generally by assembling and/or regulating protein net-
works (Harris and Lim, 2001; Lee and Zheng, 2010). Disruption
of the complexes formed by PDZ domains and their ligands
can trigger profound alterations in the relevant signaling path-
ways (Yanagisawa et al., 1997; Aarts et al., 2002; Hou et al.,
2010). Comparisons with other models of signals controlled by
PDZ domains (Yanagisawa et al., 1997; Hou et al., 2010) suggest
that a peptide could inhibit cell proliferation or trigger apoptosis
by disrupting a crucial cellular interaction, in this case between
PTPN4-PDZ and the PDZ-BS of a yet unidentified endogenous
PTPN4 ligand (see Figure S1 available online). By doing so it
could annihilate the anti-apoptotic function of PTPN4. Using
this rationale, we expect that: (1) disruption of the protection
against cell death by the RABV peptide would also occur with
peptides stemming from already known PTPN4-PDZ partners,All rights reserved
Figure 1. Peptide Sequences and Their Affinities for PTPN4-PDZ
Sequence alignment of the C termini PDZ-BS of nine peptides sorted
according to their KD value for PTPN4-PDZ as measured by NMR (Pre´haud
et al., 2010): Cyto8-RETEV (optimized sequence); GluN2A-16 and GluD2-13
encompassing the C-terminal sequences of endogenous partners of PTPN4-
PDZ, GluN2A, and GluD2, respectively; Cyto13-att from the ERA-NIV RABV
strain; Cyto13-vir from the CVS-NIV RABV strain; EIRL-13 from the CVS-B2c
RABV strain; DARL-13 from the vampire bat RABV strain; the chimeric peptide
Cyto9-ESDV encoding the PDZ-BS -RETEVCOOH with the core of Cyto13-att;
and Cyto9-D corresponding to Cyto13-att truncated from its PDZ-BS. Cationic
residues are in blue, anionic residues in red, and hydrophobic residues in
white.
Figure 2. Induction of Death in U373MG Astrocytoma Cells Is
Related to Peptide Affinity for PTPN4-PDZ
(A) U373 MG cells express PTPN4. The cells were treated with primary PTPN4
antibody followed by FITC-conjugated secondary antibody (line) or with
secondary antibody alone (black histogram). Specific index of fluorescence
(SFI) = 4. SFI >1.25 was considered positive.
(B) Kinetics of peptide loading. U373MG cells were treated with 25 mM FITC-
TAT-Cyto9-D. Peptide loading in nonpermeabilized live cells was analyzed by
flow cytometry 10, 20, 40, 60, 120, and 180 min after treatment. The gray
histogram corresponds to the background fluorescence of untreated cells. The
SFI was 1.5, 1.6, 1.8, 1.7, 2.4, and 8.5, respectively.
(C) Cell death was induced by a 3 hr peptide treatment in n independent
experiments: Cyto9-D (n = 9), Cyto13-vir (n = 4), Cyto13-att (n = 10), Cyto9-
ESDV (n = 10), GluN2A-16 (n = 4), and Cyto8-RETEV (n = 4). Cell death
(percentage [%] of dead cells among cells having loaded the peptide is indi-
Structure
Structural Design of Glioblastoma Killer Peptidessuch as the GluN2A subunit of the N-methyl-D-aspartate
receptor (NMDAR) (Hironaka et al., 2000); (2) the induction of
cell death by peptides encoding the PDZ-BS targeting PTPN4
would be related to the affinity of the peptide for PTPN4-PDZ;
and (3) improved death induction could be obtained by opti-
mizing the peptide sequence, using the structural information
gathered from several PDZ/peptide complexes.
Here, we establish that the ability of cell-permeable peptides
of viral origin, as well those originated from endogenous ligands
of PTPN4, to promote death of human glioblastoma correlates
with the affinity they display in vitro for PTPN4-PDZ. NMR and
X-ray structural data of PTPN4-PDZ bound to the C-terminal
sequence of GluN2A and to the viral peptides led us to identify
the structural basis for the recognition of these families of
sequences by PTPN4-PDZ. Using our structural data, we design
a peptide of high affinity for PTPN4-PDZ enhancing markedly its
cell death capacity.
cated by blue stars) is plotted against 1/KD values. See also Table S1.RESULTS
Peptide Affinity for PTPN4-PDZ and Killing Efficiency
We synthesized nine peptides: four viral peptides (Cyto13-att,
Cyto13-vir, EIRL-13, and DARL-13); the C-terminal sequences
of two already known endogenous partners of PTPN4-PDZ
(GluN2A-16 and GluD2-13); a chimeric peptide encoding the
PDZ-BS of GluN2A and the core of Cyto-att (Cyto9-ESDV);
Cyto13-att truncated from its PDZ-BS (Cyto9-D); and the opti-
mized peptide sequence Cyto8-RETEV. The affinity of these
peptides for PTPN4-PDZ was measured by NMR titration (Fig-
ure 1). The killing efficiency of five Tat-conjugated peptides
exhibiting various affinities for PTPN4-PDZ was estimated in
U373 MG (Figure 2C), a human glioblastoma cell line expressing
PTPN4 (Figure 2A).Structure 19, 1518–1After a three hour exposure of U373MG to the peptides,
a period of time that allows for maximal peptide entry (Figure 2B),
the induction of cell death was assayed by propidium iodide (PI)
assay. All peptides displayed a similar capacity to enter the cells.
Cyto9-D, the peptide lacking the last four amino acids does not
interact with PTPN4-PDZ because it lacks the PDZ-BS, induced
a low level of death (7%); Cyto13-vir, which has a low affinity for
PTPN4-PDZ (dissociation constant [KD] of 560 mM), did not
increase cell death above this baseline level (8%), whereas
Cyto13-att (KD = 160 mM) triggered the death of more than
14% of cells (Pre´haud et al., 2010). Therefore, the single Q > E
mutation increases the binding affinity enough to significantly
promote the death of glioblastoma cells by the cell-penetrating
peptide. GluN2A-16, which binds PTPN4-PDZ in vitro with524, October 12, 2011 ª2011 Elsevier Ltd All rights reserved 1519
Table 1. Crystallographic and Structure Refinement Statistics
PTPN4/Cyto13-att PTPN4/GluN2A16
Crystal Form
Space group P212121 P212121
Unit cell (A˚, ) 53.43, 53.70,
81.80
51.58, 51.68,
190.90
90, 90, 90 90, 90, 90
Molecules per
asymmetric unit
2 4
Data Collectiona
Resolution 34.37–1.43 95.45–1.91
Range (A˚) (1.51–1.43) (2.01–1.91)
Number of unique reflections 42,795 38,978 (4,287)
Completeness (%) 96.7 (96.7) 96.1 (74.7)
Multiplicity 3.5 (3.6) 4.2 (2.1)
Rmerge (%)
b 6.8 (30.1) 4.3 (30.9)
<I/s (I)> 10.9 (4.2) 21.1 (2.0)
Refinement
R factor (%)c 19.2 21.7
Rfree (%)
d 20.4 24.7
Rmsd bond length (A˚)
(angle [])
0.010 (1.41) 0.010 (1.17)
Ramachandran Plote
Most favored (%) 100 99.16
Additional allowed (%) 0 0.84
Outliers (%) 0 0
PDB entry 3NFK 3NFL
aValues in parentheses refer to statistics in the highest bin.
bRmerge = Sj(I  <I>)/S (I).
c R factor = SjFobs  Fcalcj/S Fobs.
dRfree was calculated with 5% of the data excluded from the refinement.
eCategories were defined by MolProbity.
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Structural Design of Glioblastoma Killer Peptideshigher affinity (KD = 42 mM), triggered death in 29% of the glio-
blastoma cell population, a 2-fold increase compared to
Cyto13-att. To test whether residues upstream of position 3
impact affinity and function, the chimeric peptide Cyto9-ESDV
was studied. The KD value of Cyto9-ESDV for PTPN4-PDZ
increased from 42 mM, the KD of the parent peptide GluN2A-
16, to 85 mM, and the capacity to trigger death decreased by
half. Glioblastomas were also treated with the antitumoral agent
shepherdin. Shepherdin is a cell-permeable peptidomimetic that
triggers tumor cell death by antagonizing the complex formed
between the anti-apoptotic and mitotic regulator survivin and
the molecular chaperone HSP90 (Plescia et al., 2005). A 5 hr
treatment with 50 mM shepherdin induces glioblastoma death
in a range similar to that obtained with Cyto13-att (data not
shown).
Altogether, these data indicate that the affinity of the last four
residues of a putative PDZ-BS for PTPN4-PDZ is a critical deter-
minant for the induction of cell death. We established that the
killing efficiency of the peptide is closely reflected by its respec-
tive affinity for the PTPN4-PDZ. According to the scenario de-
picted in Figure S1, it appears that a threshold value in the affinity
of the competing peptide for the PDZ domain of PTPN4 has to be
reached, corresponding roughly to a KD lower than 500 mM.
Structure of the PTPN4-PDZ/Viral Peptide Complex
To investigate the specificity of PTPN4-PDZ for the attenuated
RABV G protein, the crystal structure of the complex formed
by PTPN4-PDZ and Cyto13-att was solved by molecular re-
placement at 1.4 A˚ resolution (Table 1).
PTPN4-PDZ adopts a typical PDZ fold comprising five
b strands and two a helices (Figures 3A and 3D). Only the last
five C-terminal peptide residues of Cyto13-att (-GETRLCOOH)
were well ordered in the crystal, and the peptide was inserted
into the PDZ-binding pocket in a conventional mode (Figure 3B).
PTPN4-PDZ possesses the interaction network specific to
class I PDZ domains and recognizes the consensus peptide
sequence X-S/T-X-FCOOH, where X is any residue, and F is a
hydrophobic residue. At position 1, the electron density
beyond the Cg atom of the R residue is not clearly assigned.
This cationic side chain is completely exposed to the solvent,
surrounded by positively charged residues (R527, R546, and
K587), and does not contact any PTPN4-PDZ residues. Position
3 is a critical determinant of the PTPN4-PDZ/Cyto13-att
interaction. The side-chain carboxyl of E3 forms a bifurcated
H-bond with the hydroxyl of the S545 and N531 amine groups.
E3 is also strongly stabilized by hydrophobic contacts involving
its Cb-Cg carbon chain and the long aliphatic side chain of K533
in a manner quite reminiscent of the bonding patterns observed
for complexes involving PDZ domains highly structurally related
to PTPN4-PDZ, the a1- and b2-syntrophin-PDZ (PDB entry
2PDZ and 2VRF, respectively). Finally, the carbonyl oxygen of
G-4 forms an H-bond with the amide nitrogen of Q538.
Although PDZ domain classification is essentially based on
positions 0 and 2, numerous studies have emphasized the
importance of the other positions, 1, 3, and 4, crucial for
PDZ/PDZ-BS interactions (Lim et al., 2002; Stiffler et al., 2007).
Indeed as described above, E3 is involved in an extended inter-
action network with residues of the PTPN4-PDZ b sheet. In con-
trast, residues occupying positions 1 and 4 of Cyto13-att do1520 Structure 19, 1518–1524, October 12, 2011 ª2011 Elsevier Ltdnot appear to be optimal for the interaction with PTPN4-PDZ
(KD = 160 mM), likely accounting for the fact that the overall
affinity remains rather weak for a PDZ/PDZ-BS interaction,
more generally in the 1–10 mM range (Harris and Lim, 2001).
Structural Consequences of the E/Q Mutation
When affinities of the Cyto13-vir and Cyto13-att peptides for
PTPN4-PDZ were compared, a 4-fold difference in KD was
noted, Q3 having a higher KD than E3 (Figure 1) (Pre´haud
et al., 2010). We used NMR spectroscopy to characterize a
potential structure/affinity relationship that could explain this
difference in affinity between the two viral peptides. First, back-
bone dynamics from 15N relaxation measurements revealed an
overall rigid structure of PTPN4-PDZ and no detectable changes
in the dynamic behavior of the two Cyto13-att and Cyto13-vir
complexes (Figure S2). The strongest NMRchemical shift pertur-
bations on PTPN4-PDZ induced by the binding of Cyto13-vir
compared to that of Cyto13-att correspond to residues N531,
K533, and S545 (Pre´haud et al., 2010). This mapping agrees
with our present crystal structure of the PTPN4-PDZ/Cyto13-
att complex in which these residues are in contact with
Cyto13-att E3. In previously described structures of postsyn-
aptic density protein 95 (PSD95)-PDZ3 bound to peptidesAll rights reserved
Figure 3. Structures of PTPN4-PDZ Bound to Cyto13-att and GluN2A-16
(A) Superposition of PTPN4-PDZ bound to Cyto13-att (light green/green in A and B) and GluN2A-16 (light blue/blue in A and C). Peptides enter the PDZ-binding
pocket delimited by the b2 strand, a2 helix, and carboxylate-binding loop 526GRFGF530, a conserved PDZ signature.
(B and C) Close-up views of the PTPN4-PDZ/peptide-binding sites. Important residues are shown as sticks in CPK colors. Peptides form an antiparallel b sheet
with the b2 strand via a complete set of intermolecular canonical backbone H-bonds (black dashed lines). Other intermolecular H-bonds are shown in orange
dashed lines.
(D) Secondary-structure elements in PTPN4-PDZ.
Structure
Structural Design of Glioblastoma Killer Peptidescontaining Q or E residues at position3 (1BE9 for -KQTSVCOOH
and 1TP5 for -KETWVCOOH), the H-bond length of S339(Og)$$$
E3(Oε2) (2.4 A˚) is shorter than the bridge S339(Og)$$$
Q3(Oε2) (2.9 A˚). This observation is consistent with the fact
that charged H-bonds are generally stronger than uncharged
bonds. We carefully examined the NMR chemical shifts of
H-bonding amide protons (HN), which correlate with the strength
of H-bonds (Wagner et al., 1983). Surprisingly, this analysis re-
vealed that the b2/b3/b4 canonical H-bond network in close
vicinity of the E/Q mutation is locally strengthened in Cyto13-
vir compared to the Cyto13-att complex (Figures 4A and 4B).
This fine-tuned structural rearrangement leads to a favorable
energetic contribution, which partially balances the unfavorable
replacement of the bifurcated and charged N531(Hd22)$$$
E3(Oε2)$$$S545(Hg) H-bonds with neutral ones involving the
isosteric residue Q3. Such a compensatory effect could
explain the small variation in the binding free energies of complex
formation with Cyto13-vir compared to Cyto13-att, DDG0 = RT
ln(KD(Cyto13-vir)/KD(Cyto13-att)) = 0.76 kcal.mol
1, corre-
sponding to the 4-fold difference in affinity.
In conclusion slight modifications in the interaction network at
the PDZ-BS lead to the drastic functional effect reported for the
E > Q change, which is sufficient to abrogate the ability of
the PDZ-BS to recruit PTPN4 and to deny the virulent strain
the capacity to trigger cell death.
The vampire bat strain of RABV is another RABV strain that
does not trigger apoptosis (data not shown). We analyzed the
complex formed by PTPN4-PDZ with the C-terminal sequenceStructure 19, 1518–1of G protein of this strain, which is terminated by a PDZ-BS,
-DARLCOOH, corresponding to a class II motif (X-F-X-FCOOH).
This PDZ-BS very weakly interacts with PTPN4-PDZ with a KD
of 1285 mM, a hydrophobic residue at position 2 strongly
destabilizing the complex (Figure 1). Similar low affinity for
PTPN4-PDZ has been measured for another viral C-terminal
sequence (from CVS-B2C RABV strain) that encodes an I at
position 2 corresponding also to a class II motif, -EIRLCOOH.
Altogether, these data indicate that PTPN4-PDZ interacts
specifically with the PDZ-BS sequences of class I.
Structure of the PTPN4-PDZ/Endogenous Peptide
Complex
Two endogenous partners of PTPN4-PDZ are known: the
orphan ionotropic glutamate receptor, GluD2 terminated by
-RGTSICOOH and GluN2A terminated by -ESDVCOOH. Their
terminal peptides (GluD2-13 and GluN2A-16, respectively)
display affinities for PTPN4-PDZ, slightly better than the one
observed for the viral peptide Cyto13-att (Figure 1). The corre-
sponding KD values are equal to 128 mM for the former and to
42 mM for the latter. In order to define the peptide positions
where an improvement in the interaction could be noticed, the
structure of the PTPN4 PDZ domain complexed with the more
affine of these two peptides, GluN2A-16, was determined.
The structure of the PTPN4-PDZ/GluN2A-16 complex solved
at 1.9 A˚ resolution was found to be very similar to the PTPN4-
PDZ/Cyto13-att complex, with a root-mean-square deviation
(rmsd) of 0.21 A˚ (Figures 3A and 3C). The overall structure of524, October 12, 2011 ª2011 Elsevier Ltd All rights reserved 1521
Figure 4. Effect of E/Q Mutation on PTPN4-PDZ
(A) Differences in PTPN4-PDZ amide proton chemical
shifts between PTPN4-PDZ/Cyto13-att and PTPN4-PDZ/
Cyto13-vir complexes, DdHN = dHN(att) - dHN(vir). The
residues that shifted most upfield in the PTPN4-PDZ/
Cyto13-att complex are labeled in green and correspond
to a weakening of the corresponding H-bonds. Likewise,
downfield shifts are in magenta and correspond to
strengthening. Upfield shifts of approximately 0.1 ppm
correspond to H-bond lengthening of roughly 2–5 ppm.
Residues K533, G534, V544, S545, and G563 are located
in the b sheet formed by strands b2, b3, and b4, and K587
is located on the face of the a2 helix pointing toward the
peptide.
(B) Region of the PTPN4-PDZ/Cyto13-att structure
showing the b sheet formed by strands b2, b3, and b4 (light
green) and the Cyto13-att peptide (green), and the corre-
sponding H-bond network (black and red dotted lines).
Nitrogen and oxygen atoms are in blue and red, respec-
tively. As monitored by the changes in amide proton
chemical shifts, the H-bonds depicted by green dotted
lines are weakened in the PTPN4-PDZ/Cyto13-att com-
plex compared to the PTPN4-PDZ/Cyto13-vir complex,
where the two charged N531(Hd22)$$$E3(Oε2)$$$
S545(Hg) H-bonds (orange/cyan residues and red dotted
lines) are replaced by uncharged bonds involving
Q3(Oε1).
Structure
Structural Design of Glioblastoma Killer PeptidesPTPN4-PDZ was not affected by peptide binding. Only the last
five C-terminal residues of GluN2A-16 were resolved.
At position 1, the D side chain was well defined, in contrast
to R-1 of Cyto13-att. D-1 forms an H-bond with the N531 side-
chain amine group of the PDZ domain. Therefore, an acidic
residue is more favorable at the penultimate position of the
peptide. The nature of the residue at position 1 probably
makes a significant contribution to the 4-fold increase in affinity
between Cyto13-att and GluN2A-16 for PTPN4-PDZ. Further-
more, the interaction network of the conserved E3 residue
was similar in both cases. I-4 was well defined in the crystal;
its side chain is at a van der Waals distance from the imidazole
group of H579, and its carbonyl group is H-bonded to the
amino group of the Q538 side chain. A cationic residue at posi-
tion 4 is strongly preferred in highly structurally related PDZ
domains (Kurakin et al., 2007). In the case of a1-syntrophin,
an ionic bond occurs between K-4 of the ligand and D151 at
the N terminus of the a2 helix, an anionic position conserved
in PTPN4-PDZ (D580) (Schultz et al., 1998). Finally, in the
chimeric peptide Cyto9-ESDV in which the PDZ-BS of GluN2A
is inserted into the Cyto-att core, the affinity for PTPN4-PDZ
dropped by a factor of 2 compared to the native GluN2A
peptide. The flexibility of Cyto9-ESDV due to the presence of
the glycine doublet at positions 4 and 5, and the substitution1522 Structure 19, 1518–1524, October 12, 2011 ª2011 Elsevier Ltd All rights reserveof I-4 by a glycine residue (Lim et al., 2002), are
likely responsible for this effect.
Tailoring Best-Suited Peptides
by Structural Analysis
The identification of the most crucial determi-
nants of ligand recognition by PTPN4-PDZ led
us to conceive an optimized peptide leading totighter interactions with the phosphatase and, consequently, to
enhanced capacity of cell death. Considering that positions 0,
2, and 3 are involved in an extended interaction network with
residues of the PTPN4-PDZ, we focused our sequence
optimization on positions 1 and 4. We postulated that a long
acidic residue at position 1 and cationic residue at position 4
could induceadditional crucial contactswith surrounding residues
of the PDZ domain. We proposed that the PDZ-BS -RETEVCOOH
could be an optimized binding partner for PTPN4-PDZ. The
chimeric peptide encoding the PDZ-BS -RETEVCOOH with the
core of Cyto13-att (Cyto8-RETEV) displays a KD for PTPN4-PDZ
that drastically decreases to 1 mM (Figure 1). The higher affinity
of Cyto8-RETEV for PTPN4-PDZ (a 160-fold increase com-
pared to the starting viral sequence, Cyto13-att, and a 40-fold
increase compared to the most affine endogenous PTPN4 ligand,
GluN2A-16) correlatively enhances the efficiency of the peptide to
induce glioblastoma cell death, whereas GluN2A-16 triggered
death in 29%of the cells, this valuewas enhanced twice, reaching
66% with Cyto8-RETEV (Figure 2C; Table S1).
DISCUSSION
We established a relationship between the affinity of peptides
for PTPN4-PDZ and their ability to provoke glioblastoma celld
Structure
Structural Design of Glioblastoma Killer Peptidesdeath. The structures of PTPN4-PDZ complexed to viral and
endogenous peptides allowed us to identify the structural deter-
minants required for ligand recognition and to design a new
sequence displaying a higher affinity for PTPN4-PDZ. Among
the peptides tested in this study, this optimized peptide is indeed
the best PTPN4-PDZ binding partner and the best inducer of cell
death. These findings identify the key role of the PTPN4 PDZ
domain in the mechanism controlling death in tumor cells.
They strongly support the simple mechanism, depicted in Fig-
ure S1, by which a peptide could abolish this function.
Two other members of the nonreceptor phosphotyrosine
phosphatase family contain either one (PTPN3) or five
(PTPN13) PDZ domains. Intriguingly, they are both involved in
the control of tumor cell death. PTPN13 (also termed PTP-
BAS, PTPL1, PTP1E, or FAP-1) is a negative regulator of CD95
(Fas)-mediated apoptosis involved in human pancreatic adeno-
carcinoma and colon cancer cells (Ungefroren et al., 2001; Yana-
gisawa et al., 1997). The interaction between PTPN13-PDZ
and the PDZ-BS of CD95 is crucial for PTPN13 activity, likely
by allowing dephosphorylation of CD95 and by altering its
membrane localization. In addition the recruitment of the second
PTPN13 PDZ domain by a peptide mimicking the PDZ-BS of
CD95 is sufficient to promote Fas-mediated apoptosis in a colon
cancer cell line (Yanagisawa et al., 1997). PTPN3 (also termed
PTPH1) has been described as an activator of RAS oncogenesis
in colorectal cancer cells. Hou et al. (2010) demonstrated that
RAS-mediated oncogenesis requires the cooperation of the
p38g MAP kinase with PTPN3 via the formation of a complex
between the single PDZ of PTPN3 and the PDZ-BS of this
serine/threonine kinase: the recruitment of the PTPN3-PDZ by
a peptide mimicking the C-terminal sequence of the p38g MAP
kinase is sufficient to block the effect of PTPN3 on RAS onco-
genesis. Altogether, these results point out the critical role
played by the interaction of phosphatase PDZ domains with
the PDZ-BS of their respective ligands for controlling apoptosis
or oncogenesis.
PTPN3 and PTPN4 are in fact very similar. They present
the same global architecture; they also display a strong
sequence identity (71% for PDZ and 65% for PTP). In these
two cases a similar mechanism has been proposed to explain
their proliferative and anti-apoptotic functions, implying the
cooperation of their PDZ and catalytic domains for the dephos-
phorylation of a phosphotyrosine residue, present on their
respective ligands (Hou et al., 2010; Pre´haud et al., 2010). In
the PTPN3 instance the ligand is the p38g MAP kinase, and
the regulatory role of the dephosphorylation event has been
documented. In the model a specific PDZ-BS/PDZ interaction
allows presentation of the phosphotyrosine substrate to the
PTP domain of the phosphatase and leads to an efficient
catalysis.
It is then expected that an enhanced specific abrogation of
the anti-apoptotic function of PTPN4 will be obtained by target-
ing both the PDZ site of interaction and the catalytic center. This
promising possibility is now under investigation. In any case
the present results show that an efficient disruption of specific
PTP-PDZ/ligand interactions can be obtained via a simple opti-
mization of candidate pro-death sequences with the help of
structural design, already opening new avenues for antiprolifer-
ative therapies.Structure 19, 1518–1EXPERIMENTAL PROCEDURES
Cells
Human grade III U373MG astrocytoma cells (HTB 17; ATCC) were propagated
as previously described (Lafon et al., 2005).Detection of Synthetic Peptide Entry and Cell Death
Peptides were conjugated to the HIV-1 Tat domain and labeled with a FITC
molecule as previously described (Pre´haud et al., 2010). U373MG cells
(250,000 cells per well in 1 ml culture medium) were treated with FITC-conju-
gated peptides (25 mM). Three hours posttreatment, cells were detached by
trypsin treatment, washed in phosphate buffer (SPB) Ca2+Mg2+, and assayed
for peptide entry and cell death. Membrane permeation, a marker of cell death,
was measured by detecting the passage of PI (Annexin V Kit; R&D Systems).
Cells were analyzed by flow cytometry. A total of 30,000 cells was sampled
for each analysis. Results were given as percentages of dead cells among
peptide-loaded cells.Sample Preparation
Expression and purification of PTPN4-PDZ samples for NMR and crystallo-
genesis were performed as described in the Supplemental Experimental
Procedures. Peptides were synthesized in solid phase using an Fmoc strategy
(Covalab).NMR Experiments
NMR data were recorded at 298 K on a Varian Inova 600 MHz spectrometer
equipped with a cryogenically cooled triple-resonance pulsed field gradient
probe. NMR titration experiments to measure PTPN4-PDZ/peptide affinities
were performed as previously described (Pre´haud et al., 2010) using
0.16 mM 15N-labeled PTPN4-PDZ with stepwise additions of unlabeled
peptides.Crystallization, Data Collection, and Structure Determination
Crystallogenesis is described in Table S2 and Supplemental Experimental
Procedures. Details on X-ray data collection, processing, molecular replace-
ment using the atomic model of PTPN4 (PDB code 2VPH), and refinement
are given in Table 1 and Supplemental Experimental Procedures.ACCESSION NUMBERS
The atomic coordinates and structure factors have been deposited in the
Brookhaven Protein Data Bank under accession codes 3NFK for PTPN4-
PDZ/Cyto13-att and 3NFL for PTPN4-PDZ/GluN2A-16.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and two tables and can be found with this article online at
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